AbbVie Inc.

- AbbVie expects higher adjusted net interest expense in 2024, around $2 billion, primarily due to financing the ImmunoGen and Cerevel acquisitions. - In 2024, adjusted net interest expense increase reflects the recent earlier close of the ImmunoGen acquisition and the pending Cerevel acquisition. - These acquisitions imply AbbVie has done or plans to do financing through debt to support these transactions. - The company anticipates an increase in dilution to adjusted earnings per share related to these acquisitions ($0.42 dilution combined). - No explicit mention of new equity fundraising in the current transcripts. - Overall, current/future fundraising appears to be primarily through debt related to acquisitions rather than equity issuance.

- AbbVie recently completed the acquisition of ImmunoGen, accelerating entry into the solid tumor market and strengthening the oncology pipeline. - The integration of ImmunoGen has been seamless with high-caliber talent joining AbbVie. - AbbVie remains on track with the pending acquisition of Cerevel, expected to close mid-year, which will augment the neuroscience portfolio. - The company continues to advance early-stage development opportunities, adding novel programs and partnerships in oncology and immunology. - Continued investments are being made in R&D to discover and develop new medicines supporting long-term growth. - In aesthetics, ongoing investments in consumer activation and new product launches, particularly in China, are planned to support market recovery starting in the second half of 2024.

- AbbVie expects robust revenue growth in 2025 and acceleration beyond, driven by expanding operating margins (Page 6). - Ex-Humira growth platform delivered over 15% revenue growth in Q1 2024, with key products like Skyrizi growing above 50% in their fifth year on market (Page 1). - Continued double-digit revenue growth expected from multiple key products including Venclexta, Vraylar, and Ubrelvy (Page 1). - Growth in immunology expected via Skyrizi and Rinvoq, with strong access anticipated through 2025 and beyond (Pages 6, 8). - The aesthetics business expects a recovery in China starting in the second half of 2024, with investment in consumer activation and new product launches (Page 8). - Solid contracts and payer relationships are anticipated to maintain favorable market access and volume stability, especially for Skyrizi (Pages 6, 8). - Humira volume decline aligns with expectations, with some volume shifting to other AbbVie products, contributing to overall growth (Pages 6, 8).

- AbbVie expects robust revenue growth in 2025, with growth accelerating in 2026 and beyond, driven by Part D benefit redesign and expanding margins (Rob Michael, COO). - Typically, earnings are expected to grow faster than revenue due to margin expansion; however, in 2025, net interest expense may limit earnings growth slightly but still deliver solid growth. - AbbVie raised 2024 adjusted EPS guidance by $0.16 to a range of $11.13 to $11.33, reflecting strong top and bottom-line performance. - The ex-Humira growth platform grew over 15% in Q1 2024, with several products showing double-digit revenue growth. - Long-term outlook signals high-single-digit revenue CAGR through the end of the decade. - Earnings per share in Q1 2024 was $2.31, $0.11 above guidance, reflecting strong execution across the portfolio.

The transcript provided does not contain specific information on current or expected orderbook or pending orders for AbbVie. The discussion mainly focuses on sales performance, pricing dynamics, market competition, contract negotiations, and business outlooks for various drugs and sectors (e.g., Humira, aesthetics, Skyrizi) rather than explicit orderbook data or pending order volumes. - No specific data on current or expected orderbook or pending orders mentioned. - Focus is on sales, pricing benefits, volume pressures, and contract updates. - Discussions relate to market performance, competitive positioning, and financial outlooks for FY 2024. - Insights provided on contractual approaches and reimbursement dynamics rather than order volumes. - No quantifiable backlog or order volume figures disclosed in these pages.